News
08/07/2001
Press Release
Isonics Partners with Major Wafer Manufacturer
Isonics Corporation (NASDAQSC:ISON/ISONW, FRANKFURT: IO9) announced that it has entered into an silicon-28 marketing agreement with one of the world’s leading wafer manufacturers.
The agreement calls for Isonics to supply silicon-28 raw materials and for the partner to produce silicon-28 epitaxial wafers and sample them to interested customers worldwide. The wafers will be manufactured in the partner’s U.S. facility.
Dr. Stephen Burden, Isonics’ Vice President of Semiconductor Materials, commented, “This relationship is an important step towards commercialization of silicon-28. Our wafer partner is a qualified supplier with all of our target customers. Supplying silicon-28 state-of-the-art wafers in 200 and 300 mm diameters through an existing supplier is necessary for a number of companies that want to evaluate silicon-28. Should demand for commercial quantities of epitaxial wafers result from this effort, we would be in an excellent position to supply them in a short period of time.”
Isonics is a world leader in isotopically engineered materials and produces isotopically pure silicon-28 chemicals and wafers for the semiconductor industry. Isonics also markets and sells stable isotopes for the health care industry such as carbon-13 for diagnostic breath tests and drug design, and oxygen-18 for positron emission tomography (PET) imaging. Stable isotopes can be thought of as ultra pure materials. This high degree of purification provides enhanced properties as compared to natural materials. Additional information may be obtained at www.isonics.com.
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company’s control. Other important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company’s 10-KSB for the year ended April 30, 2000, and its quarterly report on Form 10-QSB for the nine months ended January 31, 2001, both as filed with the Securities and Exchange Commission, which include the Company's cash flow difficulties, dependence on significant customers, and rapid development of technology, among other risks. In assessing forward- looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company’s filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Contact: Cameron Associates Michael Brod, 212/245-8800 michael@cameronassoc. com or Isonics Corporation James E. Alexander, 303/279-7900 |
